Trial Profile
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms SCALE Teens
- Sponsors Novo Nordisk
- 07 May 2022 Results of secondary analysis assessing outcome of anti-obesity medication trials presented at The joint congress on obesity of the European Association of the Study of Obesity and the International Federation for the Surgery of Obesity and metabolic disorders-European Chapter.
- 07 May 2022 Results of secondary analysis assessing sociodemographic and baseline characteristics presented at The joint congress on obesity of the European Association of the Study of Obesity and the International Federation for the Surgery of Obesity and metabolic disorders-European Chapter.
- 26 Mar 2021 According to a Novo Nordisk media release, Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda is expanded for the treatment of obesity in adolescents aged 12 to 17 years.The CHMP opinion is based on the results of a this trial.